ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ische...(pre-clinicalstudies designed to further ...),Health

Date:1/4/2008

pre-clinical studies designed to further optimize the ultrasound delivery parameters. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include: data from our clinical trials under our SonoLysis program may not be positive or ultimately support the filing of an NDA; and, we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of January 4, 2008, and the Company undertakes no duty to update this information. A more complete description of these risks can be found in the Company's filings with the Securities and Exchange Commission.

Contacts:

ImaRx Therapeutics, Inc. The Ruth Group

Jennifer Marshall Sara Ephraim (investors)

VP Corporate Dev. & Investor Relations sephraim@theruthgroup.com

jlmarshall@imarx.com Jason Rando (media)

(520) 770-1259 jrando@theruthgroup.com

'/>"/>

SOURCE ImaRx Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
2. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
3. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
4. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
5. Replidyne Provides Strategic Update
6. BioCryst Provides Forodesine HCl Update
7. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
10. Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success